A citation-based method for searching scientific literature

Kenneth B Gordon, Bruce Strober, Mark Lebwohl, Matthias Augustin, Andrew Blauvelt, Yves Poulin, Kim A Papp, Howard Sofen, Lluís Puig, Peter Foley, Mamitaro Ohtsuki, Mary Flack, Ziqian Geng, Yihua Gu, Joaquin M Valdes, Elizabeth H Z Thompson, Hervé Bachelez. Lancet 2018
Times Cited: 278



C Paul, J-P Lacour, L Tedremets, K Kreutzer, S Jazayeri, S Adams, C Guindon, R You, C Papavassilis. J Eur Acad Dermatol Venereol 2015
Times Cited: 211




List of shared articles



Times cited

Disease activity and treatment efficacy using patient-level Psoriasis Area and Severity Index scores from tildrakizumab phase 3 clinical trials.
K B Gordon, K Reich, J J Crowley, N J Korman, F T Murphy, Y Poulin, L Spelman, P S Yamauchi, A M Mendelsohn, J Parno,[...]. J Dermatolog Treat 2022
11

PASI 100 response rates in moderate to severe psoriasis: a systematic literature review and analysis of clinical practice guidelines.
Isabel Belinchón Romero, Esteban Dauden, Carlos Ferrándiz Foraster, Álvaro González-Cantero, Jose Manuel Carrascosa Carrillo. J Dermatolog Treat 2022
3

Efficacy, safety, usability, and acceptability of risankizumab 150 mg formulation administered by prefilled syringe or by an autoinjector for moderate to severe plaque psoriasis.
Andrew Blauvelt, Kenneth B Gordon, Patricia Lee, Jerry Bagel, Howard Sofen, Benjamin Lockshin, Ahmed M Soliman, Ziqian Geng, Tianyu Zhan, Gabriela Alperovich,[...]. J Dermatolog Treat 2022
2

Immunobiologicals in dermatology.
Dimitri Luz Felipe da Silva, Elisa Nunes Secamilli, Mariana Valbon Beleli, Juliana Yumi Massuda, Andrea F E C Franca, Renata F Magalhães. An Bras Dermatol 2022
0

Number Needed to Treat Network Meta-Analysis to Compare Biologic Drugs for Moderate-to-Severe Psoriasis.
Craig L Leonardi, Kyoungah See, Russel Burge, Zhuoer Sun, Ying Zhang, Lotus Mallbris, Alyssa Garrelts, Richard B Warren. Adv Ther 2022
1

Impact of Pharmacokinetic and Pharmacodynamic Properties of Monoclonal Antibodies in the Management of Psoriasis.
Karine Rodríguez-Fernández, Víctor Mangas-Sanjuán, Matilde Merino-Sanjuán, Antonio Martorell-Calatayud, Almudena Mateu-Puchades, Mónica Climente-Martí, Elena Gras-Colomer. Pharmaceutics 2022
2



Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.
Emilie Sbidian, Anna Chaimani, Ignacio Garcia-Doval, Liz Doney, Corinna Dressler, Camille Hua, Carolyn Hughes, Luigi Naldi, Sivem Afach, Laurence Le Cleach. Cochrane Database Syst Rev 2022
0

Break on through: The role of innate immunity and barrier defence in atopic dermatitis and psoriasis.
H C Hawerkamp, C M R Fahy, P G Fallon, C Schwartz. Skin Health Dis 2022
3

Racial and ethnic diversity of US participants in clinical trials for acne, atopic dermatitis, and psoriasis: a comprehensive review.
Anjana Sevagamoorthy, Patrick Sockler, Christine Akoh, Junko Takeshita. J Dermatolog Treat 2022
0

Characterization of insufficient responders to anti-tumor necrosis factor therapies in patients with moderate to severe psoriasis: real-world data from the US Corrona Psoriasis Registry.
Abby S Van Voorhees, Marc A Mason, Leslie R Harrold, Ning Guo, Adriana Guana, Haijun Tian, Vivian Herrera, Bruce E Strober. J Dermatolog Treat 2021
4

Characterization of insufficient responders to ustekinumab in patients with moderate-to-severe psoriasis in the US Corrona Psoriasis Registry.
Abby S Van Voorhees, Marc A Mason, Leslie R Harrold, Ning Guo, Adriana Guana, Haijun Tian, Vivian Herrera, Bruce E Strober. J Dermatolog Treat 2021
0

Placebo Response in Phase 3 Trials of Systemic Therapies for Moderate-to-Severe Plaque Psoriasis: A Systematic Review and Meta-Analysis.
Danni Ambikaibalan, Anna Sophie Quaade, Anne-Sofie Halling, Jacob P Thyssen, Alexander Egeberg. Dermatology 2021
1